Effect of Hypoxia on the Expression and Production of Fractalkine in Pulmonary Artery Smooth Muscle Cells and Pulmonary Microvascular Endothelial Cells

CHEN Xiao-ju, CHENG De-yun, FAN Li-li

Abstract

To investigate the effect of hypoxia on the expression and production of fractalkine (FKN) in cultured rat pulmonary artery smooth muscle cells (PASMCs) and pulmonary microvascular endothelial cells (PMVECs). Methods PASMCs and PMVECs from SD rat were cultured in vitro,and were exposed to hypoxia for 12 h,24 h and 48 h. The expressions of fractalkine mRNA and protein in PASMCs and PMVECs were measured by the methods of in situ hybridization and immunohistochemistry. The fractalkine concentrations in supernatant fluid of cultured PASMCs and PMVECs were measured by enzyme-linked immunosorbent assay. Results ① Compared with the control group, the expression and production of fractalkine in PASMCs did not increase after the treatment of hypoxia for 12 hours (P>0.05), but increased after being treated with hypoxia for 24 hours (P<0.05), and became more significant after 48 hours (P<0.01). ②Compared with the control group, there were no differences of FKN concentrations in supernatant fluid of PMVECs, FKN mRNA and protein levels in PMVECs after being treated with hypoxia for 12 hours, 24 hours or 48 hours (P>0.05). Conclusion Hypoxia stimulates the synthesis and secretion of fractalkine in cultured rat PASMCs.

 

Keywords: Hypoxia, Fractalkine, Pulmonary artery smooth muscle cells, Pulmonary microvascular endothelial cells


Full Text:

PDF


References


Thomas DA. Stefa Faderl S. Corte J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103 (12);4396-4407.

Thomas DA. Philadelphia chromosome-positive acute lymphocytic leukemia;a new era of challenges. Hematology Am So Hematol Educ Program,2007:435-443.

Nimmanapalli R. Bhalla K. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncob 2002; 14 (6): 616-620.

Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program.2006:219-225. Radujkovic A.Schad M.Topaly J,et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL—inhibition of P-glycoprotein by 17- AAG. Leukemia, 2005; 19(7): 1198-1206.

Hirayama C, Watanabe H, Nakashima R. et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1 «contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res, 2008;25(4);827-835.

Sharom FJ. ABC multidrug transporters; structure, function and role in chemoresistance. Pharmacogenomics, 2008; 9( 1 ): 105-127.

Oostendorp RL,Buckle T.Beijnen JH et al. The effect of P-gp (Mdrla/lb), BCRP (Bcrpl) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs,2009;27(1) :31-40.

Hamada A.Wantanabe H, Nakashima H, el at. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther,2003;307(2);824-828.


Refbacks

  • There are currently no refbacks.